

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**WUXI APPTEC CO., LTD.\***

**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2359)**

## **VOLUNTARY ANNOUNCEMENT IN RELATION TO CLASS ACTION LAWSUIT AGAINST SHAREHOLDERS**

The board of directors (the “**Board**”) of WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) was informed that on February 21, 2019 (New York time), a former small shareholder (the “**Plaintiff**”) of WuXi PharmaTech (Cayman) Inc. (“**WuXi PharmaTech**”) had filed a class action lawsuit (the “**Lawsuit**”) in the United States District Court for the Southern District of New York against WuXi PharmaTech, five of its then directors and/or members of the senior management (including Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao) and other members of the buyer consortium involved in the delisting of WuXi PharmaTech from New York Stock Exchange completed on December 10, 2015 (the “**Delisting**”), seeking for, *inter alia*, damages and reasonable legal costs allegedly caused by material false statements and omissions contained in the then disclosure documents relating to the Delisting. No amount of damages was specified at this stage. Reference is made to the prospectus of the Company dated December 3, 2018 for details of the Delisting.

As at the date of this announcement, WuXi PharmaTech is an indirect shareholder of the Company, holding approximately 6.92% of the total issued shares of the Company through its wholly-owned subsidiary, WuXi AppTec (BVI) Inc. The Company is not named as a defendant in the Lawsuit and was not a party responsible for the disclosure documents in relation to the Delisting. The Company considered that the Lawsuit will not have any material adverse impact on its operations and financial position nor will it distract the attention of the management of the Company from managing on the Company’s business.

As disclosed in the prospectus dated April 23, 2018 in respect of the listing of the Company’s A shares on the Shanghai Stock Exchange (the “**A Share Prospectus**”), (i) the percentage of the votes voted for and against the Delisting by the then shareholders of WuXi PharmaTech at the then shareholders’ meeting was 97.49% and 1.59%, respectively; and (ii) as at the date of the A Share Prospectus, WuXi PharmaTech had not received any objection notice from its shareholders as of the date of the shareholders’ meeting approving the Delisting or encountered any dissenting shareholder lawsuit in respect of the Delisting. The legal advisors engaged for the listing of the Company’s A

shares also confirmed that the Delisting was carried out in compliance with the federal securities laws of the United States and the New York Stock Exchange Listed Company Manual.

To the knowledge of the Company, WuXi PharmaTech and the other defendants are confident in putting forward a strong defense for the Lawsuit and have engaged a professional team of U.S. securities litigators to contest vigorously and forcefully. The Company is also aware that class action lawsuits in relation to privatization or mergers and acquisitions of public companies are fairly common in the United States and are often initiated by plaintiff's law firms or certain types of investors.

The Company will follow closely with the relevant parties on the progress of the Lawsuit and will make further announcement(s) as and when appropriate in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board  
**WuXi AppTec Co., Ltd.**  
**Dr. Ge Li**  
*Chairman*

Hong Kong, February 25, 2019

*As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Mr. Xiaozhong Liu, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.*

\* *For identification purpose only*